8 results
The first aim of the study is to investigate whether DCS addition to exposure therapy enhances symptom reduction in PD+AGO. The second objective of the study is to establish the optimal timing of administration of DCS (30 minutes before or directly…
The present study is aimed at testing the effects of D-cycloserine in addition to exposure treatment sessions in PTSD patients, in a randomized double blind placebo controlled study.
The objective for this study is threefold. First we will determine whether DCS addition to behavioural exposure therapy may enhance fear extinction and improve symptoms in BDD. Our hypothesis is that improvement will occur and at a faster rate than…
treatment outcome in OCD. Objective: The objective for this study is fourfold. First we will determine whether DCS addition to behavioural exposure therapy may enhance fear extinction and improve symptoms in OCD. Our hypothesis is that improvement…
The aim of this pilot-study is to establish the potential efficacy of acute doses of 50 mgs D-cycloserine (DCS), a partial NMDA agonist, in accelerating and/or augmenting the effect of exposure and response prevention (ERP) in the treatment of…
Dual Primary Objectives:* To determine if apixaban is noninferior to VKA (INR target range 2.0-3.0) on the combined endpoint of ISTHmajor or clinically relevant non-major bleeding in patients with NVAF who develop ACS or undergo PCI withplanned…
The primary objective is to test the role of NMDA receptor-dependent learning in an experimental model of conditioned nocebo effects on self-reported pain (sub-study 1) and itch (sub-study 2). Secondary objectives are to examine the role of NMDA…
Co-primary (tested in parallel for non-inferiority):- To compare daprodustat to rhEPO for CV safety (non-inferiority)- To compare daprodustat to rhEPO for Hgb efficacy(non-inferiority)